title: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.
abstract: A molecular basis for memory failure in Alzheimer's disease (AD) has been recently hypothesized, in which a significant role is attributed to small, soluble oligomers of amyloid beta-peptide (A beta). A beta oligomeric ligands (also known as ADDLs) are known to be potent inhibitors of hippocampal long-term potentiation, which is a paradigm for synaptic plasticity, and have been linked to synapse loss and reversible memory failure in transgenic mouse AD models. If such oligomers were to build up in human brain, their neurological impact could provide the missing link that accounts for the poor correlation between AD dementia and amyloid plaques. This article, using antibodies raised against synthetic A beta oligomers, verifies the predicted accumulation of soluble oligomers in AD frontal cortex. Oligomers in AD reach levels up to 70-fold over control brains. Brain-derived and synthetic oligomers show structural equivalence with respect to mass, isoelectric point, and recognition by conformation-sensitive antibodies. Both oligomers, moreover, exhibit the same striking patterns of attachment to cultured hippocampal neurons, binding on dendrite surfaces in small clusters with ligand-like specificity. Binding assays using solubilized membranes show oligomers to be high-affinity ligands for a small number of nonabundant proteins. Current results confirm the prediction that soluble oligomeric A beta ligands are intrinsic to AD pathology, and validate their use in new approaches to therapeutic AD drugs and vaccines.
authors.affiliation: Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208, USA.
authors.forename: Yuesong
authors.initials: Y
authors.lastname: Gong
authors.forename: Lei
authors.initials: L
authors.lastname: Chang
authors.forename: Kirsten L
authors.initials: KL
authors.lastname: Viola
authors.forename: Pascale N
authors.initials: PN
authors.lastname: Lacor
authors.forename: Mary P
authors.initials: MP
authors.lastname: Lambert
authors.forename: Caleb E
authors.initials: CE
authors.lastname: Finch
authors.forename: Grant A
authors.initials: GA
authors.lastname: Krafft
authors.forename: William L
authors.initials: WL
authors.lastname: Klein
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000032:analysis* / Q000378:metabolism*; D000818:Animals; D001665:Binding Sites; D001923:Brain Chemistry; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000737:chemistry / Q000378:metabolism; D015151:Immunoblotting; D008024:Ligands; D017774:Long-Term Potentiation; D009474:Neurons / Q000378:metabolism; D009842:Oligopeptides / Q000032:analysis*; D010446:Peptide Fragments / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014020:Tissue Extracts / Q000032:analysis
chemical_list: D016229:Amyloid beta-Peptides; D008024:Ligands; D009842:Oligopeptides; D010446:Peptide Fragments; D014020:Tissue Extracts; C098994:amyloid beta-protein (1-43)